BREAKING NEWS
Massachusetts Cannabis Officials Look Forward to Changes Following Federal Rescheduling of Medical Marijuana
In a significant shift, the Trump administration has reclassified state-licensed medical marijuana from a Schedule I to a Schedule III drug, allowing for more flexibility in its regulation and research. The move is expected to bring about changes for medical marijuana licensees in Massachusetts, including tax breaks and improved patient access.
The Cannabis Control Commission (CCC) has been preparing for this possibility and is looking forward to the benefits that this change may bring. “We have been preparing for the possibility of rescheduling for years, and we look forward to this change potentially providing benefits for medical marijuana licensees such as changes to federal tax status under 280E, new research opportunities, and improved support for patient access,” said CCC Executive Director Travis Ahern.
The reclassification will allow for tax breaks for medical marijuana operators, easing of barriers for research into medical use, and potentially broadening the potential for clinical and biotech research. The CCC is reviewing the order and plans to hold a wider briefing meeting with state regulators on Friday.
This change comes as support for the legalization of marijuana continues to rise, with 64% of Americans in favor of legalization, according to a recent Gallup poll. The Trump administration’s move is seen as a significant step forward in the country’s cannabis policy.
“This action recognizes what Americans have long known, cannabis is medicine,” said Michael Bronstein, president of the American Trade Association for Cannabis and Hemp.
The CCC’s efforts to modernize the state’s cannabis law, signed by Governor Maura Healey, will also be complemented by the federal shift. The new law allows for increased possession limits, expansion of potential delivery services, and removal of the retail license cap, among other changes.
As the state continues to navigate the changing landscape of cannabis policy, the CCC remains committed to ensuring a safe and regulated industry for patients and consumers.
